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Background: Alzheimer’s disease (AD), the most common cause of dementia among neurodegenerative diseases,
afflicts millions of elderly people worldwide. In addition to amyloid-beta (Aβ) peptide and phosphorylated tau, lipid
dysregulation is suggested to participate in AD pathogenesis. However, alterations in individual lipid species and
their role in AD disease progression remain unclear.
Methods: We performed a lipidomic analysis using brain tissues and plasma obtained from mice expressing mutated
human amyloid precursor protein (APP) and tau protein (Tg2576×JNPL3) (APP/tau mice) at 4 (pre-symptomatic
phase), 10 (early symptomatic) and 15 months (late symptomatic).
Results: Levels of docosahexaenoyl (22:6) cholesterol ester (ChE) were markedly increased in APP/tau mice
compared to controls at all stages examined. Several species of ethanolamine plasmalogens (pPEs) and
sphingomyelins (SMs) showed different levels between brains from APP/tau and control mice at various stages of
AD. Increased levels of 12-hydroxyeicosatetraenoic acid (12-HETE) during the early symptomatic phase were
consistent with previous reports using human AD brain tissue. In addition, 19,20-dihydroxy-docosapentaenoic acid
(19,20-diHDoPE) and 17,18-dihydroxy-eicosatetraenoic acid (17,18-diHETE), which are produced from
docosahexaenoic acid and eicosapentaenoic acid via 19,20-epoxy-docosapentaenoic acid (19,20-EpDPE) and
17,18-epoxy-eicosatetraenoic acid (17,18-EpETE), respectively, were significantly increased in APP/tau brains during
the pre-symptomatic phase, and concomitant increases occurred in plasma. Several arachidonic acid metabolites
such as prostaglandin D2 (PGD2) and 15-hydroxyeicosatetraenoic acid (15-HETE), which have potential
deteriorating and protective actions, respectively, were decreased in the early symptomatic phase of APP/tau
mice. Significant decreases in phosphatidylcholines and PEs with polyunsaturated fatty acids were also detected in
the late symptomatic phase, indicating a perturbation of membrane properties.
Conclusion: Our results provide fundamental information on lipid dysregulation during various stages of human AD.
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Alzheimer’s disease (AD) afflicts millions of elderly people
worldwide and is the most common cause of dementia
among neurodegenerative diseases. AD symptoms include
impaired memory, aphasia, and visuospatial deficits while
the histopathological changes of AD are characterized by
senile plaques, neurofibrillary tangles, and lipid granule
accumulation. The major molecular component of senile
plaques is aggregated amyloid-β (Aβ) peptide, which is
generated from the amyloid precursor protein (APP) via
sequential cleavage by β-secretase and the γ-secretase
complex [1]. AD onset is assumed to be related to Aβ pep-
tide polymerization. On the other hand, neurofibrillary
tangles are composed of aberrantly phosphorylated tau
protein [2].
In addition to the above pathological features, numerous
studies reported a link between lipids and AD. In general,
membrane lipids provide a milieu for transmembrane pro-
teins and can modulate their function. Indeed, γ-secretase
activity is affected by the lipid composition of the mem-
brane with sphingolipids and cholesterol increasing and
phosphatidylinositols decreasing its activity [3,4]. Lipid
carbon chain length and double bond position also affect
γ-secretase activity. Hypercholesterolemia reportedly ac-
celerates intraneuronal accumulation of Aβ oligomers and
subsequent synapse loss, resulting in memory impairment
in AD model mice [5]. Moreover, ω-3 polyunsaturated
fatty acids were shown to have possible roles in AD pre-
vention [6]. The docosahexaenoic acid (DHA) content of
phospholipids (PLs) was lower in brain tissue and plasma
of AD patients compared to those without cognitive
impairment [7]. In addition, neuroprotectin D1, which
is derived from DHA, was related to suppression of
Aβ42-induced neurotoxicity [8]. Several lipidomic ana-
lyses for AD were recently reported. For instance, an
analysis of postmortem brain tissues obtained from pa-
tients with late-onset AD showed enrichment in
lysobisphosphatidic acids, sphingomyelins (SMs), gan-
glioside GM3, and cholesterol esters (ChEs) as well as
novel region-specific lipid anomalies that were poten-
tially linked to AD pathogenesis [9]. However, our
current knowledge of the overall changes in lipids re-
lated to AD, especially for the time-course of their
changes, remains low.
Animal models are extensively used to study AD patho-
genesis since brain samples can be obtained from pre-
symptomatic to late stages of AD, which allows analysis of
pathophysiological changes at different disease stages. A
recent study showed that some lipid dysregulation oc-
curred in postmortem AD brain tissues, including in-
creased levels of ganglioside GM3 and ChEs, which was
consistent with changes seen in AD mouse models [9],
and supports the validity of using animal models to study
AD disease mechanisms. In this study, we performed aglobal lipid metabolomic analysis using brain tissues and
plasma obtained from transgenic mice expressing both
mutated human APP and tau proteins [10] at 4 months
(pre-symptomatic), 10 months (early disease stage), and
15 months (late stage). We focused not only on lipid
changes observed in the brain but also on those that were
consistently changed in both brain and plasma because




We used female transgenic mice hemizygous for
transgenes encoding both human mutated APP and tau
(APP/tau mice) as AD model mice. The mice were
generated by crossing Tg2576 male transgenic mice
hemizygously expressing human APP containing Swedish
type mutations (Lys670Asn, Met671Leu) with JNPL3
female transgenic mice homozygously expressing mu-
tant P301L four-repeat tau proteins. Wild-type tau fe-
males crossed with wild-type APP male mice were used
as a control (no transgenes). Two-month-old mice were
purchased from Taconics Farms, Inc. (Hudson, NY,
USA) and raised to 4 (pre-symptomatic), 10 (early stage
of symptoms), and 15 months (late stage) of age. At the
given time point, mice were anesthetized with 2.0-2.5%
isoflurane in the atmosphere and blood from the infer-
ior vena cava was collected in tubes containing EDTA-
2Na for plasma preparation. After blood collection,
mouse brains were excised, and the cerebral hemi-
spheres without the cerebellum were weighed and fro-
zen in liquid nitrogen before storage at −80°C. Each
group consisted of 5 mice except for the 15-month-old
APP/tau mice (N=3). All animal experiments were
performed in accordance with the Guidelines for Animal
Experimentation and with approval from the Ethics
Committee of Animal Care and Experimentation of the
National Center for Geriatrics and Gerontology, Japan.
Assay of human Aβ40 and tau proteins
The right cerebral hemisphere from each animal (ca. 150
mg) was homogenized as described below in the section
describing lipid extraction. After removal of methanol with
a centrifugal vacuum concentrator (TOMY), Aβ40 in brain
tissues (2 mg) was extracted by homogenization in 0.2 ml
70% formic acid with a small Dounce homogenizer and
centrifugation at 100,000 × g for 1 h at 4°C in an ultracen-
trifuge (Optima MAX-E, Beckman Coulter, Tokyo, Japan).
The supernatants were recovered and stored at −80°C
until analysis. Frozen formic acid extracts were thawed on
ice and neutralized with 20 volumes of 1 M Tris base.
Within 1 h of neutralization, Aβ40 levels in the extracts
were determined by an Enzyme-Linked Immunosorbent
Assay (ELISA) kit for human Aβ40 (Wako Pure Chemical
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turer’s instructions. Total protein in the extracts was
assayed by a PierceW BCA™ Protein Assay Kit (Thermo
Fisher Scientific Ltd., Yokohama, Japan).
Human tau protein in brain tissue from each mouse
was analyzed according to the method described by
Lewis et al. [10]. Two mg of EtOH-free homogenized
brain tissue from each mouse was homogenized with a
small Dounce homogenizer in 0.2 ml of tris-buffered sa-
line (TBS) and centrifuged at 100,000 × g for 1 h at 4°C.
The supernatant was collected as the TBS-soluble frac-
tion. The pellet was homogenized similarly in 0.2 ml of
0.8 M NaCl and 10% sucrose in TBS, and after centrifu-
gation at 150,000 × g for 15 min at 4°C, the supernatant
was brought to 1% sarkosyl and incubated at 37°C for 1
h. The mixture was then centrifuged at 150,000 × g for
30 min at 4°C whereupon the supernatant and precipi-
tate were collected as the sarkosyl-soluble and -insoluble
fraction, respectively. TBS-soluble and sarkosyl-soluble
fractions were combined and defined as the soluble frac-
tion. Human tau levels in the soluble and sarkosyl-
insoluble fractions were determined using an ELISA kit
for human tau (Lifetechnology Japan Ltd., Tokyo, Japan).
The sarkosyl-insoluble fraction was dissolved in 0.1 ml
of 70% formic acid and neutralized with 20 volumes of
1M Tris base immediately before ELISA determination.
Lipid extraction
Total lipids from right cerebral hemisphere tissues or
plasma were extracted using Bligh & Dyer’s (BD)
method with minor modifications [11]. The right cere-
bral hemisphere from each animal (ca. 150 mg) was ho-
mogenized with zirconia beads in 1 mL of methanol at
4°C using a cell disruptor (TOMY), and the equivalent
of 10 mg tissue was transferred into glass tubes. Plasma
(100 μl) diluted with methanol was also transferred into
glass tubes. A mixture of internal standards (ISs) was
added to tissue homogenates or plasma: 1, 2-dipalmitoyl
D6-3-sn glycerophosphatidylcholine (16:0/16:0PC-d6, 40
nmol/10 mg tissue or 20 nmol/100 μl plasma, Larodan,
Malmo, Sweden), 1,2-caprylin-3-linolein (250 pmol and
20 nmol, Larodan), 13C-labelled tripalmitin (tripalmitin-
1,1,1-13C3, 250 pmol and 2 nmol, Larodan), deuterated
prostaglandin E2 (PGE2-d4, 5 ng in both tissue and
plasma, Cayman Chemical, Ann Arbor, MI, USA) and
deuterated leukotriene B4 (leukotriene B4-d4, 5 ng in
both tissue and plasma, Cayman Chemical). Then,
chloroform, methanol and 20 mM potassium phosphate
(Kpi) buffer were added to achieve a volume ratio of
buffer/methanol/chloroform = 0.8/2/1, and mixed vigor-
ously for 5 min. Phase separation was achieved by
adding 1 ml each of chloroform and 20 mM Kpi buffer
and vortexing. The mixture was centrifuged at 1,000 × g
for 10 min. For brain tissue, both the upper aqueouslayer and bottom organic layer were collected. For
plasma, 100 mM KCl/methanol/chloroform (48/47/3)
was further added to the remaining organic samples
after the upper aqueous layer was collected. After mixing
vigorously for 5 min and centrifugation at 1,000 x g for
10 min, only the bottom organic layer was collected.
Samples of the organic layer were dried under a gentle
stream of nitrogen, and then dissolved in chloroform-
methanol (1:1) at a concentration of 10 mg (tissue
weight)/ml or 100 μL (plasma volume)/ml, and were
stored at −90°C until use (BD sample). To distinguish
alkenylacyl and alkyl PL species with the same exact
mass as 34:1 ethanolamine plasmalogen (pPE) and 34:2
alkylacyl PE, a small aliquot of each BD sample was hy-
drolyzed using 0.5 N HCl as described previously (BD
acid hydrolysis sample) [12].
Samples of the aqueous layer (3.2 ml) were subjected
to solid extraction to obtain oxidative fatty acids. First,
samples were diluted 10-fold using water adjusted to
pH 3.0 with 1N HCl, and then applied to Oasis SPE
cartridges (60 mg, Waters, Millford, MA, USA) precon-
ditioned with 3 ml each of methanol and Milli Q water.
After columns were washed with 3 ml of Milli-Q water
followed by 3 ml hexane, the oxidative fatty acids were
eluted with 3 ml methyl formate (MF). The MF fraction
was dried under nitrogen, dissolved in chloroform-
methanol (1:1) at a concentration of 10 mg (tissue
weight)/ml or 100 μL (plasma volume)/ml, and stored
at −90°C until use.
Lipid metabolite analysis by reverse-phase liquid
chromatography (RPLC)-time of flight mass spectrometry
(TOFMS)
Total lipid samples (BD samples and BD acid hydrolysis
samples) were analyzed by electrospray ionization (ESI)-
TOFMS (LCT Premier XE; Waters Micro-mass, Waters)
interfaced with an Acquity UPLC System (Waters). The
MS was operated in a W-optics mode with 10,000 and
8,000 resolution in the positive and negative modes, re-
spectively, using dynamic range extension. The scan
range of the instrument was set at a mass-to-charge ra-
tio (m/z) of 150–1200, and three functions (positive and
negative ion modes, and another negative ion mode for
in-source fragmentation) were recorded simultaneously
for lipid species identification and quantification. The
capillary voltage in the positive ion mode was set at 3.0
kV and the cone voltage 40 V, whereas in the negative
ion mode the capillary and cone voltage was 2.5 kV and
-40V, respectively. In in-source fragmentation of the
negative ion mode, the aperture 1 voltage was set at 60
V. The desolvation gas was set to 600 L h−1 at a
temperature of 350°C; the cone gas was set to 50 L/h
and the source temperature was 120°C. The data ac-
quisition rate was 0.5 s with a 0.01 s interscan delay.
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sure accuracy and reproducibility. A lock-mass of leu-
cine enkephalin at 0.6 ng/mL in 50:50 acetonitrile:
water containing 0.1% formic acid was used for the
positive and negative ion modes ([M+H]+ = 556.2771
and [M+H]- = 554.2615) with a flow rate of 5.0 μL/min via
a lock spray ionization source. The data were collected in
the centroid mode using MassLynx (Waters).
Before the RPLC-ESI-TOFMS analysis, the dried BD
and BD acid hydrolysis samples were redissolved in
chloroform/methanol/isopropanol (1:2:4) supplemented
with 0.2% formic acid and 0.028% ammonia at a final
concentration of 10 mg tissue/ml solution or 100 μl
plasma/ml solution, and filtered through a 0.2 μm pore
size polyvinylidene difluoride membrane filter (Millipore,
Bedford, MA, USA). The injection volume was fixed at 2
μL, and an ACQUITY UPLC BEH C18 column (1.7 mm
i.d. × 150 mm, 1.7 μm) was used for separation. The col-
umn temperature was maintained at 45°C. The flow rate
of the mobile phase was 70 μL/min. Mobile phase A
consisted of acetonitrile/methanol/water = 18/18/4 (0.1%
formic acid and 0.028% ammonia), while mobile phase B
consisted of isopropanol (0.1% formic acid and 0.028%
ammonia). The linear gradient increased from 0 to 15% B
over 5 min, from 15% to 30% B for the next 20 min, from
30% to 45% B during the next 15 min, from 45% to 60% B
for the next 10 min, from 60% to 80% B for the next
5 min, and immediately ramped to 85% B for the final
12 min. Blank runs were carried out randomly between
samples to confirm that there was no chromatographic
carryover.
Structural analysis of lipid metabolites by RPLC-ESI-linear
ion trap-MS
For structural analysis of PL, SM and triacylglycerol
(TAGs) species, BD samples were also analyzed using a
Finnigan LTQ linear ion trap mass spectrometer (Thermo
Fisher Scientific Inc. San Jose, CA, USA) interfaced with a
Shimadzu Prominence HPLC system (Shimadzu, Kyoto,
Japan). To analyze the fatty acid composition of PLs and
SMs, data-dependent MS/MS (MS2) or MS3 analysis was
performed in negative ion mode with an ion spray voltage
of 4 kV and a scan range of m/z = 400–1000 as described
previously [12]. For structural analysis of TAGs, data-
dependent MS2 analysis was performed in the positive ion
mode with an ion spray voltage of 4.5 kV and a scan range
of m/z = 300–2000. The trap fill-time was 50 ms (full
mass analysis) and 100 ms (MSn analysis) in both ion
modes. Nitrogen was used as a sheath gas (25 arbitrary
units), and helium as a collision gas at a collision energy
setting of 35%. BD samples were treated in the same way as
RPLC-ESI-TOFMS analysis and applied onto an ACQUITY
UPLC BEH C18 column (1.7 mm i.d. × 100 mm, 1.7 μm,
Waters) kept at 45°C. LC conditions were the same asthose in RPLC-ESI-TOFMS analysis. The classes of indi-
vidual lipid species and their fatty acid compositions were
determined with these data, together with RPLC-ESI-
TOFMS data with exact mass and in-source fragmenta-
tion information.
Targeted analysis of oxidative fatty acids by RPLC-ESI-
triple quadrupole MS/MS
Oxidative fatty acids were measured as reported previ-
ously [13]. Briefly, MF fractions in solid extraction were
analyzed by a 5500QTRAP quadrupole-linear ion trap
hybrid mass spectrometer (AB Sciex, Framingham, MA,
USA) interfaced with an ACQUITY UPLC System
(Waters) equipped with an ACQUITY BEH C18 column
(1.7 mm i.d. × 150 mm, 1.7 μm, waters), kept at 40°C. Sam-
ples were eluted with a mobile phase of water/acetate
(100:0.1, v/v, solvent A’) and acetonitrile/methanol (4:1, v/v,
solvent B’). The gradient increased from 27 to 50% B’ in
five min, from 50 to 80% B’ in the next 30 min, from 80 to
100% B’ in the next five min, and kept at 100% B’ for ten
min with flow rates of 50 μL/min (0 – 35 min), 50–100
μL/min (35 – 40 min), and 100 μL/min (40 – 50min). Ana-
lysis was performed with multiple reaction monitoring in
the negative ion mode, with ion spray voltage, -4500 V;
curtain (nitrogen), 10 arbitrary units; collision gas (ni-
trogen), 6 arbitrary units and a gas temperature of
350°C. We simultaneously measured 31 arachidonic
acid metabolites, 14 eicosapentaenoic acid (EPA) me-
tabolites, 13 DHA metabolites, 2 docosapentaenoic acid
metabolites, and 2 linolenic acid metabolites. Declustering
potential, collision energy and collision cell exit potential
were optimized for each individual metabolite using
authentic standard compounds (Cayman Chemical). In
plasma samples from 15 month old control mice, one
sample was omitted from the measurement due to in-
strumental problems (N=4).
Data processing
RPLC-ESI-TOFMS data were subsequently processed
using the 2DICAL software package (2 Dimensional
Image Converted Analysis of LCMS, Mitsui Knowledge
Industry Co. Ltd., Tokyo, Japan) [14]. This software
allowed detection and alignment of the ion-peak inten-
sity derived from biomolecules identified with m/z and
column retention times (RTs) in an amount of collected
data. The main parameters of 2DICAL were set as fol-
lows: RT range 0.1–60.0 min and 0–37.5 min in the
positive and negative ion modes, respectively, a mass
range 400 to 1200 m/z, mass tolerance 0.3 m/z, mass
window 0.3 m/z, an RT window of 0.60 min, and noise
elimination level 2. The resulting three-dimensional
matrix contains an arbitrarily assigned peak index (RT-
m/z pairs) and ion intensity information (variables). The
extracted ion peaks of each metabolite were normalized
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was used as an IS to normalize metabolites of PLs, lysoPLs,
SMs, ceramides (Cers) and diacylglycerols (DAGs), which
eluted at 0.1 to 37.5 min in RPLC. To normalize the TAG
and ChE metabolites that eluted at 37.5 to 60 min,
Tripalmitin-1,1,1-13C3 (Larodan Fine Chemicals) was used.
Data for oxidative fatty acids were subsequently
processed with Analyst™ (ver. 1.5.1, AB Sciex) software
or MultiQuant™ Software (Version 2.1, AB Sciex). The
integrated peak area of each metabolite was normalized
to that of the IS (leukotriene B4-d4).
Statistical and multiple classification analysis
The IS-normalized peak list from RPLC-TOFMS analysis
was first exported to the SIMCA-P+ for multivariate
data analysis (Infocom Corp., Tokyo, Japan). Orthogonal
partial least-squares-discriminant analysis (OPLS-DA)
was used to select variables that strongly contributed to
the difference between the two mice groups of the same
ages. The Welch’s t-test was then applied to assess statis-
tical measures between the APP/tau and wild-type mice.
For oxidative fatty acid analysis, Welch’s t-tests were
directly applied to the results with normalized peak
areas.
Results
Expression levels of Aβ40 and tau proteins in APP/tau
mice
We measured the protein expression levels of Aβ40
and tau in APP/tau mice by ELISA. In APP/tau mice,
Aβ40 accumulated in the brain from 10 months of age
(Additional file 1: Figure S1). On the other hand, soluble
human tau protein was expressed at similar levels from 4
through 15 months of age. The levels of sarkosyl-insoluble
tau appeared to be slightly higher at 10 and 15 months
than at 4 months, but these differences did not reach stat-
istical significance among all ages tested. In wild-type
mice, both Aβ40 and human tau were under the detection
limit at all tested ages.
Analysis of brain tissues
We first performed lipidomic analysis of BD samples
extracted from brain tissues of APP/tau and wild-type
mice at 4, 10, and 15 months of age using RPLC-ESI-
TOFMS. When creating a two-dimensional map of RT
versus m/z values of the individual precursor ion peaks
in the positive ion mode, the intensities of a few spots
that were apparently identified as ChEs were higher in
APP/tau mice compared to wild-type mice at 4 months
(Additional file 2: Figure S2). Likewise, at 10 and 15
months, these ChE spots retained the higher intensities
in APP/tau mice compared to age-matched wild-type
mice (data not shown). In the positive ion mode, a total of
803 peaks were detected and divided into two groupsbased on their retention time (RT). For RTs of 0.1–37.5
min, the 695 peaks contained mainly glycerophospholipids
such as PLs, lysoPLs and sphingolipids such as SMs and
Cers. For RTs of 37.5–60 min, the 108 peaks represented
neutral lipids such as TAGs and ChEs. Peaks in each RT
category were then separately processed by OPLS-DA
(Additional file 3: Figure S3) because glycerophospholipids
and neutral lipids are the two major classes of lipid metab-
olites with different physical properties. The OPLS-DA
score plots for brain tissues indicated that APP/tau and
wild-type mice could be reliably discriminated using
established models at 4 (Additional file 3: Figure S3), 10
and 15 months (data not shown).
To detect with high confidence the metabolites con-
tributing to the discrimination between the two groups
(APP/tau vs. wild-type) that were located at extreme
ends of “S” of the OPLS-DA loading S-plot, we screened
variables from this plot with threshold values of w[1] > |
0.05|, p(corr)[1] > |0.6|, which represent the magnitude
of contribution (weight) and reliability (correlation), re-
spectively. For brain tissue from 4-month-old animals
(pre-symptomatic phase), 9 and 12 metabolites in total
(RT, 0.1-60 min) that exceeded this threshold value
showed higher and lower levels in APP/tau compared to
wild-type mice, respectively (Additional file 3: Figure
S3). In addition, 8 and 8 metabolites at 10 months (early
disease stage) and 5 and 58 metabolites at 15 months
(late stage) had higher and lower levels in APP/tau com-
pared to wild-type mice, respectively, and met the cri-
teria (data not shown). The relative quantification data
of the identified metabolites that meet the OPLS-DA
loading S-plot criteria (unidentified peaks were omitted)
were summarized in Additional file 4: Table S1. Of these
metabolites, the levels of 2, 3 and 2 species were signifi-
cantly increased and 4, 3 and 24 were significantly de-
creased in APP/tau mice compared to wild-type mice at
4, 10 and 15 months, respectively, by Welch’s t-test
(Table 1). Particularly, docosahexaenoyl-ChE (22:6 ChE)
and 38:2 pPE (p18:1/20:1) were consistently increased
and decreased, respectively, across the tested ages in
APP/tau mice compared to wild-type mice (Figure 1).
Other ChE species such as 18:1ChE were under the de-
tection limit (data not shown). Notably, many pPE spe-
cies (e.g., 36:2pPE (p18:1/18:1), 36:4pPE (p16:0/20:4),
38:4pPE (p16:0/22:4), 38:4pPE (p18:0/20:4), 40:4pPE
(p18:0/22:4), 40:6pPE (p18:0/22:6)) and SM species (e.g.,
36:2SM (d18:2/N18:0), 38:1SM (d18:1/N20:0), 34:1SM
(d18:1/N16:0)) were decreased at 15 months (Table 1).
Decreases in several phosphatidylcholines (PCs) and PEs
mainly with polyunsatulated fatty acids (PUFAs) were
also detected in the late symptomatic phase (Table 1).
As for triacylglycerol (TAG), the level of 60:12TAG
(16:0/22:6/22:6) was increased (1.33-fold) in 10 month
old animals, whereas most TAG levels were decreased in
Table 1 Fold changes in significantly changed lipids in brain tissues
Molecular species 4 months 10 months 15 months
Fold Change 1 p-value 2 Fold Change 1 p-value 2 Fold Change 1 p-value 2
Phosphatidylcholine (PC)
30:0PC (14:0/16:0) 1.35 0.026* 1.14 0.200 1.03 0.198
32:0PC (16:0/16:0) 1.02 0.815 0.87 0.093 0.83 0.011*
34:2PC (16:0/18:2) 1.32 0.190 1.63 0.014* 1.03 0.282
36:3PC (16:0/20:3) 1.06 0.550 1.07 0.441 1.28 0.029*
38:1PC (18:0/20:1) 0.84 0.092 0.87 0.155 0.77 0.010**
38:4PC (16:0/22:4) 1.07 0.462 0.92 0.279 0.86 0.011*
38:5PC (18:1/20:4) 1.10 0.104 0.93 0.426 0.88 0.021*
40:4PC (18:0/22:4) 1.05 0.596 0.91 0.188 0.84 0.003**
40:7PC (18:1/22:6) 1.00 0.984 0.90 0.615 0.87 0.021*
34:1ePC 1.04 0.542 0.92 0.338 0.86 0.029*
Phosphatidylethanolamine (PE)
38:1PE (20:0/18:1) 0.74 0.021* 0.89 0.413 0.66 0.024*
38:5PE (18:1/20:4) 0.99 0.942 0.94 0.352 0.85 0.023*
40:4PE (18:0/22:4) 1.10 0.265 0.91 0.269 0.89 0.035*
Ethanolamine plasmalogen (pPE)
36:2pPE (p18:1/18:1) 0.76 0.299 0.88 0.183 0.86 0.042*
36:4pPE (p16:0/20:4) 1.02 0.810 0.91 0.359 0.89 0.027*
38:2pPE (p18:1/20:1) 0.78 0.037* 0.83 0.037* 0.76 0.034*
38:4pPE (p16:0/22:4) 1.02 0.682 0.92 0.310 0.82 0.009**
38:4pPE (p18:0/20:4) 0.94 0.819 0.93 0.796 0.87 0.029*
40:4pPE (p18:0/22:4) 0.96 0.611 0.94 0.399 0.88 0.013*
40:6pPE (p18:0/22:6) 1.02 0.822 0.89 0.182 0.87 0.043*
Sphingomyelin (SM)
34:1SM (d18:1/N16:0) 0.98 0.863 0.97 0.675 0.76 0.007**
36:2SM (d18:2/N18:0) 0.94 0.335 0.81 0.010* 0.86 0.027*
38:1SM (d18:1/N20:0) 0.90 0.278 0.85 0.067 0.79 0.006**
42:2SM (d18:1/N24:1) 0.78 0.048* 0.86 0.388 0.60 0.066
Cerebroside
42:2cerebroside 0.81 0.045* 0.92 0.334 0.84 0.137
Diacylglycerol (DAG)
38:4DAG 0.94 0.420 0.74 0.016* 0.78 0.043*
Triacylglycerol (TAG)
52:3TAG (16:0/18:1/18:2, 16:1/18:1/18:1) 0.87 0.353 0.68 0.143 0.40 0.002**
53:6TAG 1.05 0.765 0.91 0.648 0.54 0.003**
54:4TAG (16:0/18:0/20:4) 1.09 0.463 1.04 0.801 0.31 <0.001***
60:12TAG (16:0/22:6/22:6) 0.99 0.935 1.33 0.011* 0.87 0.544
Cholesterol ester (ChE)
22:6ChE 5.22 0.002** 6.96 0.004** 5.43 0.032*
1 Fold change (ratio of APP/tau to wild-type) is the mean of N=3-5.
2 Welch’s t-test (*p<0.05, **p<0.01,***p<0.001).










Figure 1 Changes in 22:6ChE and 38:2pPE (p18:1/20:1) levels in brain tissue from APP/tau and wild-type mice. The relative levels of
metabolites are represented by the IS normalized peak heights using 16:0/16:0PC-d6 for 38:2pPE and tripalmitin-1,1,1-13C3 for 22:6ChE as ISs.
These two metabolites were significantly changed in the brain across the tested ages. *p< 0.05, **p< 0.01 by Welch’s t-test. Values are mean ± SD
of N = 3–5.
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and showed statistical significance for 52:3TAG (16:0/
18:1/18:2, 16:1/18:1/18:1), 53:6TAG and 54:4TAG (16:0/
18:0/20:4) (0.40, 0.54 and 0.31-fold, respectively) (Table 1
and Additional file 4: Table S1).
Free PUFAs and their oxidized metabolites extracted
from brain tissues were then measured using a multiple
reaction monitoring system, and 16 species were
detected (Additional file 5: Table S2). Of these, 9 spe-
cies were significantly changed between APP/tau and
wild-type mice as shown in Table 2. The numbers of
variable metabolites were 2, 7 and 0 species at 4, 10 and
15 months, respectively. No free PUFAs or their oxi-
dized metabolites were consistently changed between
APP/tau and wild-type mice across the ages tested
(Additional file 5: Table S2). Pathway analysis of arachi-
donic acid metabolites is shown in Additional file 6:
Figure S4. A marked decrease in prostaglandin D2 andTable 2 Fold changes of the significantly changed oxidized fa
Molecular species 4 months
Fold Changes 1 p-value 2 Fold
Metabolites derived from arachidonic acid
Prostaglandin D2 0.99 0.941 0.46
Thromboxane B2 1.24 0.113 0.66
12-HHT 1.19 0.149 0.67
12-HETE 0.90 0.777 1.77
15-HETE 1.03 0.747 0.71
11,12-EpETrE 0.84 0.225 0.83
14,15-EpETrE 0.85 0.053 0.79
Metabolites derived from eicosapentaenoic acid
17,18-diHETE 2.12 < 0.001*** 1.10
Metabolites derived from docosahexaenoic acid
19,20-diHDoPE 1.72 0.002** 1.20
1 Fold changes (ratio of APP/tau to wild-type) are means of N=3-5.
2 Welch’s t-test (*p<0.05, **p<0.01,***p<0.001).
HHT, hydroxy-heptadecatrienoic acid; HETE, hydroxyeicosatetraenoic acid; EpETrE, e
dihydroxydocosapentaenoic acid.15-hydroxyeicosatetraenoic acid (HETE) was observed
at 10 months (Figure 2).
Analysis of plasma
In the positive ion mode of BD samples from plasma,
385 and 308 peaks were detected on the basis of their
RT, 0.1-37.5 min and 37.5-60 min, respectively. Next, we
analyzed changes in lipid species levels in plasma by
OPLS-DA loading S-plot (data not shown) in the same
manner as for the brain tissues. At 4 months of age, 35
and 3 metabolites (RT, 0.1-60 min) with higher and
lower levels in APP/tau mice than in wild-type mice, re-
spectively, were detected. Forty-five and 9 metabolites
displayed higher and lower levels in APP/tau mice com-
pared to wild-type mice, respectively, at 10 months, and
32 and 22 were detected at 15 months. Relative quantifica-
tion results of these metabolites are shown in Additional
file 7: Table S3 (unidentified peaks were omitted) and thetty acids in brain tissues
10 months 15 months
Changes 1 p-value 2 Fold Changes 1 p-value 2














Figure 2 Changes of prostaglandin D2 and 15-HETE levels in brain tissue from APP/tau and wild-type mice. The relative levels of
metabolites are represented by the IS normalized peak areas using leukotriene B4-d4 as an IS. ***p< 0.001 by Welch’s t-test. Values are mean ± SD
of N = 3–5.
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levels between APP/tau and wild-type mice are listed in
Table 3. The levels of 23 metabolites (22 were increased
and 1 was decreased in APP/tau mice) at 4 months, 32
metabolites (26 and 6) at 10 months and 12 metabo-
lites (7 and 5) at 15 months were significantly different
between APP/tau and wild-type mice. As for PUFAs
and their oxidized metabolites, the 34 species were
detected (Additional file 8: Table S4) and, 7, 3 and 9
species levels were also significantly changed between the
two mice groups at 4, 10, and 15 months, respectively
(Table 4).
Concomitant changes in brain tissues and plasma
Finally, we assessed whether the significant changes in
lipid species were consistent for brain tissues and
plasma. We found that 34:2PC (16:0/18:2) was concomi-
tantly increased in brains (1.63-fold, p = 0.014) and
plasma (1.17-fold, p = 0.007) of APP/tau mice compared
to wild-type mice at 10 months (Tables 1 and 3). Fur-
thermore, 52:3TAG was decreased both in brain (0.4-
fold, p=0.002) and plasma (0.58-fold, p=0.045) at 15
months (Tables 1 and 3). The levels of 19,20-dihydroxy-
docosapentaenoic acid (19,20-diHDoPE) and 17,18-
dihydroxy-eicosatetraenoic acid (17,18-diHETE) in APP/tau
mice at 4 months were significantly higher both in brain
(1.72-fold, p = 0.002 for 19,20-diHDoPE and 2.12-fold,
p < 0.001 for 17,18-diHETE) and plasma (1.67-fold,
p = 0.010 for 19,20-diHDoPE and 2.11-fold, p = 0.003
for 17,18-diHETE) than those from wild-type mice
(Figure 3).
Discussion
In the present study we performed a lipidomic analysis of
brain tissue and plasma from APP/tau mice and corre-
sponding control (wild-type) mice at both presymptomatic
and post-symptomatic phases using RPLC-ESI-TOFMS,
RPLC-ESI-linear ion trap-MS, and RPLC-ESI-triple quad-
rupole MS/MS. AD brains display several characteristic
pathological features, including accumulation of amyloidplaques composed of Aβ and neurofibrillary tangles com-
posed of hyperphosphorylated tau protein. APP/tau mice
are suitable animal models to study lipid dysregulation
over very early to late stages of AD because these animals
are destined to develop the disease based on currently
proposed pathogenesis mechanisms.
In brain tissue from our model mice, 22:6ChE levels
were significantly increased in APP/tau mice compared
to controls at all stages examined. In agreement with
our results, 22:6ChE was reported to be increased in
forebrains of mutated APP/presenilin-1 mice (11-fold,
p < 0.01) and mutated APP mice (3-fold, borderline
significance), but not of presenilin-1 mice (0.9-fold) at
9–11.5 months of ages, compared with wild-type mice
[9]. In postmortem entorhinal cortex of AD patients,
increased levels of ChE (1.7-fold, p = 0.027) were also
observed, although the predominantly increased spe-
cies was different between AD humans (16:1ChE,
16:0ChE and 18:1ChE) and mice with mutated APP
(22:6ChE) [9]. The elevation in ChE levels in our
mouse model had already occurred at 4 months of age
(Figure 1) when Aβ accumulation was not yet observed
(Additional file 1: Figure S1), which supports the idea that
intracellular ChE levels regulate Aβ generation [15].
Other notable lipid dysregulation observed in brains of
APP/tau mice was the reduced levels of several pPE spe-
cies, particularly at the late stage of AD (15 months). In
brains from AD patients, plasmalogen levels were
reported to be decreased [16,17], suggesting that the
mechanisms for this reduction could be common be-
tween humans and APP/tau mice. Marked increases in
Aβ at 15 months of age might promote the formation of
reactive oxygen species, which oxidize pPE, resulting in
reduced pPE levels. It was reported that pPE decreases
γ-secretase activities [18], and that Aβ destabilized the
rate-limiting enzyme of plasmalogen synthesis, alkyl-
dihydroxyacetonephosphate synthase, through peroxi-
somal dysfunction [19]. The levels of 38:2pPE (p18:1/20:1)
were consistently decreased across the tested ages in
APP/tau mice, although the pathophysiological significance
Table 3 Fold changes of the significantly changed lipids in plasma
Molecular species 4 months 10 months 15 months
Fold Changes 1 p-value 2 Fold Changes 1 p-value 2 Fold Changes 1 p-value 2
Phosphatidylcholine (PC)
16:1LPC 0.99 0.960 0.59 0.026* 1.07 0.724
18:0LPC 1.50 0.019* 1.27 0.281 1.01 0.921
20:5LPC 3 1.45 0.011* 0.82 0.440 1.26 0.190
22:6LPC 1.45 0.011* 1.03 0.889 1.10 0.619
34:1PC (16:0/18:1) 1.24 0.037* 1.00 0.983 1.27 0.071
34:2PC (16:0/18:2) 1.27 0.053 1.17 0.007** 1.21 0.015*
34:3PC (16:0/18:3) 1.06 0.698 0.65 0.034* 0.98 0.936
35:2PC 1.68 0.030* 1.55 0.013* 1.27 0.035*
36:1PC (18:0/18:1) 1.55 0.010** 1.16 0.256 1.19 0.109
36:2PC (18:0/18:2) 1.48 0.024* 1.35 0.017* 1.11 0.139
36:5PC (16:0/20:5) 1.51 0.011* 0.81 0.509 1.40 0.374
37:2PC (19:0/18:2) 1.33 0.144 1.47 0.008** 1.26 0.071
38:3PC (18:0/20:3) 1.52 0.045* 1.38 0.209 1.17 0.497
38:4PC (18:1/20:3) 0.99 0.957 0.63 0.031* 0.82 0.137
38:5PC (18:0/20:5) 1.74 0.008** 1.08 0.783 1.24 0.266
38:5PC (18:1/20:4) 1.13 0.331 0.79 0.018* 0.84 0.149
38:7PC 1.08 0.644 0.48 0.019* 0.94 0.807
40:4PC (20:0/20:4) 1.50 0.018* 1.47 0.077 1.12 0.313
40:5PC (18:0/22:5) 1.71 0.007** 1.25 0.182 1.30 0.349
40:6PC (18:0/22:6) 1.64 0.033* 1.39 0.099 1.06 0.629
40:7PC (18:1/22:6) 1.06 0.642 0.72 0.022* 0.73 0.072
42:6PC (20:0/22:6) 1.41 0.002** 1.52 0.012* 1.38 0.110
34:2ePC (16:0e/18:2) 1.52 <0.001*** 1.81 <0.001*** 1.47 0.011*
phosphatidylinositol (PI)
38:5PI (18:0/20:5) 1.53 0.024* 0.92 0.748 2.00 0.002**
Sphingomyelin (SM)
34:1SM (d18:1/N16:0) 1.25 0.057 1.35 0.027* 1.30 0.032*
42:2SM 1.37 0.051 1.39 0.024* 1.38 0.069
42:3SM (d18:2/N24:1) 1.48 0.030* 1.22 0.061 1.30 0.141
Triacylglycerol (TAG)
52:3TAG (16:0/18:1/18:2) 1.21 0.557 1.21 0.558 0.58 0.045*
52:4TAG (16:0/18:2/18:2) 1.57 0.250 1.41 0.421 0.40 0.032*
52:5TAG (16:0/18:2/18:3) 1.04 0.903 0.74 0.314 0.49 0.011*
54:3TAG (18:0/18:1/18:2) 0.64 0.553 0.62 0.411 0.48 0.043*
54:4TAG (18:1/18:1/18:2) 0.93 0.919 0.97 0.950 0.37 0.038*
56:6TAG (18:0/18:2/20:4) 2.00 0.209 2.75 0.016* 0.82 0.500
58:10TAG (16:0/20:4/22:6) 1.40 0.311 2.07 0.020* 0.88 0.509
58:11TAG 2.44 0.038* 1.92 0.027* 1.70 0.205
58:11TAG 1.87 0.030* 1.69 0.176 1.64 0.383
58:12TAG (18:3/20:4/20:5) 2.06 0.032* 1.91 0.168 2.65 0.005**
60:10TAG 1.68 0.131 2.24 0.021* 0.90 0.762
60:11TAG (16:2/22:4/22:5) 1.43 0.178 2.04 <0.001*** 1.51 0.168
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Table 3 Fold changes of the significantly changed lipids in plasma (Continued)
60:11TAG (16:0/22:5/22:6) 1.66 0.335 1.98 0.007** 1.39 0.401
60:11TAG (18:2/20:3/22:6) 1.80 0.018* 2.13 0.005** 1.42 0.304
60:12TAG (18:2/20:5/22:5) 1.67 0.106 1.75 0.177 2.80 0.011*
60:12TAG (18:3/20:4/22:5) 1.38 0.375 2.85 0.007** 1.37 0.356
60:12TAG (18:3/20:4/22:5) 2.25 0.039* 2.08 0.068 2.81 0.087
60:12TAG (18:3/20:4/22:5) 2.29 0.154 2.04 0.021* 1.64 0.308
60:13TAG (18:2/20:5/22:6) 1.66 0.086 2.00 0.015* 2.58 0.067
62:11TAG (18:2/22:4/22:5, 16:1/22:5/24:5) 1.64 0.063 1.77 0.031* 1.58 0.232
62:12TAG (18:3/22:4/22:5) 1.56 0.147 2.27 0.003** 1.35 0.370
62:13TAG (16:1/22:6/24:6, 20:2/20:5/22:6) 2.28 0.121 1.77 0.003** 1.82 0.363
62:13TAG (18:1/22:6/22:6) 2.09 0.106 2.36 0.029* 2.53 0.272
62:14TAG (18:2/22:6/22:6) 2.25 0.119 2.45 <0.001*** 2.20 0.274
64:14TAG 1.57 0.215 2.06 0.008** 1.95 0.251
65:14TAG 1.83 0.052 2.03 <0.001*** 1.52 0.299
Cholesterol ester (ChE)
18:1ChE 0.74 0.016* 0.78 0.089 1.12 0.423
18:2ChE 1.16 0.170 1.17 0.029* 1.16 0.307
20:5ChE 1.38 0.041* 0.93 0.762 1.33 0.138
1 Fold changes (ratio of APP/tau to wild-type) are means of N=3-5.
2 Welch’s t-test (*p<0.05, **p<0.01,***p<0.001).
3 This specie was picked up not from OPLS-DA loading S-plot but manually.
Table 4 Fold changes of the significantly changed oxidized fatty acids in plasma
Molecular species 4 months 10 months 15 months
Fold Changes 1 p-value 2 Fold Changes 1 p-value 2 Fold Changes 1 p-value 2
Metabolites derived from arachidonic acid
17-HETE 1.59 0.018* 1.41 0.112 1.36 0.111
18-HETE 1.46 0.021* 1.48 0.105 1.67 0.011*
5,15-diHETE 2.02 0.002** 1.42 0.159 1.97 0.002**
Metabolites derived from eicosapentaenoic acid
8-HEPE 1.55 0.125 1.65 0.095 2.00 0.006**
15-HEPE 1.20 0.314 1.47 0.197 1.51 0.020*
17,18-EpETE 1.66 0.165 1.46 0.157 1.85 0.004**
14,15-diHETE 2.16 0.032* 1.80 0.051 2.21 0.122
17,18-diHETE 2.11 0.003** 1.51 0.116 2.22 0.004**
Metabolites derived from docosahexaenoic acid
7-HDoHE 1.28 0.336 1.46 0.102 1.46 0.044*
10-HDoHE 1.62 0.047* 1.11 0.550 1.52 0.252
19,20-diHDoPE 1.67 0.010* 1.42 0.027* 1.80 0.033*
Metabolites derived from linolenic acid
9-HOTrE(alpha) 1.64 0.202 2.53 0.023* 2.08 0.108
13-HOTrE(alpha) 1.50 0.147 1.87 0.041* 1.73 0.008**
1 Fold changes (ratio of APP/tau to wild-type) are means of N=3-5.
2 Welch’s t-test (*p<0.05, **p<0.01,***p<0.001).
HETE, hydroxyeicosatetraenoic acid; diHETE, dihydroxyeicosatetraenoic acid; HEPE, hydroxyeicosapentaenoic acid; EpETE, epoxyeicosatetraenoic acid; HDoHE,
hydroxydocosahexaenoic acid; diHDoPE, dihydroxydocosapentaenoic acid; HOTrE, hydroxyoctadecatrienoic acid .










Figure 3 Consistent changes in the levels of two ω-3 fatty acid metabolites in brain tissue and plasma. The relative levels of 19,20-
diHDoPE and 17,18-diHETE in brain tissue (A) and plasma (B) are represented by the IS normalized peak areas using leukotriene B4-d4 as an IS.
*p < 0.05, **p< 0.01, ***p < 0.001 by Welch’s t-test. Values are mean ± SD of N = 3–5.
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The elevated levels of 12-HETE observed in APP/tau mice
at early stages of AD (10 months, Table 2) were also con-
sistent with a previous report showing that brains of AD
patients exhibited higher levels of 12-HETE than control
subjects [20]. As suggested in human cases, 12-HETE may
be linked to oxidative stress and neurodegeneration in AD
as well as being involved in learning and memory processes
[21].
The decreased levels of SM species with medium-
chain fatty acids at late stages of AD were also in agree-
ment with a previous study using human postmortem
AD brains in which medium-length SMs such as d18:0/
N20:0 and d18:1/N20:0 were shown to be slightly down-
regulated (p < 0.05) [9]. These decreases might reflect
demyelination as in the case of human AD brains de-
scribed by Svennerholm and Gottfries [22]. Aβ42 was
reported to accelerate SM degradation by activating neu-
tral sphingomyelinase [23].
Increased levels of 60:12TAG bearing two DHAs
(16:0/22:6/22:6, 1.33-fold) in 10 month old animals were
in agreement with the previous report in which the
levels of 56:7TAG containing docosahexaenoic acid
(22:6FA) were increased in entorhinal cortices from AD
patients. Since DHA-conjugated ChE was also increased
in brains from APP/Tau mice at all ages tested (Figure 1),
the AD brain appears to accumulate DHA in both TAGand ChE forms during the early symptomatic phase. These
lipids might be involved in the production of DHA-
derived messenger molecules such as neuroprotectin D1,
which are reported to play neuroprotective roles in AD
brain [8]. On the other hand, most APP/tau mice TAG
levels were decreased compared with wild type mice at 15
months, particularly 52:3TAG (16:0/18:1/18:2, 16:1/18:1/
18:1), 53:6TAG and 54:4TAG (16:0/18:0/20:4). A decrease
in AA containing TAG (58:7TAG) was also observed in
the prefrontal cortices of AD patients and in forebrains
from 9–11.5 month old presenilin 1-APP mice compared
to control animals [9]. Hydrolysis of these TAGs might
thus be enhanced for their conversion into various struc-
tural and signaling lipid molecules, including eicosanoids,
DAGs, monoacylglycerols (MAG) and phospholipids.
In addition to the changes described above, significant
decreases in PCs and PEs mainly with PUFAs were also
detected during the late symptomatic phase. These phe-
nomena might reflect fatty acid chain oxidation caused
by the increased oxidative stress derived from increased
Aβ peptide levels [24]. Several arachidonic acid metabo-
lites in the brain also showed different levels when com-
paring APP/tau mice with their controls. Levels of
PGD2, which mediates neural damage by Aβ42 [25], were
lowered at 10 months (Figure 2), reflecting a possible
protective reaction in the brain. Inflammation is charac-
teristic of AD brain tissues as aggregated Aβ and
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levels of inflammatory cytokines such as interleukin-6 and
tumor necrosis factor-α [26]. While levels of some cyclo-
oxygenase (COX)-mediated metabolites such as TXB2 and
12-HHT were also decreased, others (PGE2, 6-keto PGF1α
and PGF2α) were not (Additional file 6: Figure S4). Over-
all, these results suggest that not all COX pathways but in-
stead several downstream pathways (such as PGD2
synthesis) might be impaired in AD brains during the
early symptomatic phase. 15-HETE is known to be a lig-
and for peroxisome proliferator-activated receptor γ
(PPARγ) [27] and might have anti-inflammatory activity in
the AD brain. In this context, decreases in 15-HETE levels
in the early phase of AD might promote lowered
resistance to AD progression. We also observed decreases
in both 11,12-epoxy-5,8,11-eicosatrienoic acid (11,12-
EpETrE) and 14,15-EpETrE during the early symptomatic
periods (Table 2). The roles of these decreases in AD pro-
gression should be evaluated in the future.
Because metabolites that are consistently changed in
both brain tissues and plasma from APP/tau mice com-
pared to controls could be candidate diagnostic bio-
markers for AD, we examined changes in lipid species
levels in plasma. In both brain and plasma, 34:2PC
(16:0/18:2) and 52:3TAG were consistently increased
and decreased, respectively, in APP/tau mice compared
with wild-type mice only after disease onset (10 or 15
months). Regarding oxidative fatty acid metabolites,
19,20-diHDoPE and 17,18-diHETE were consistently in-
creased in both brain tissues and plasma from APP/tau
mice before symptoms appeared at 4 months (Tables 2
and 4, Figure 3), and these increases were essentially
maintained at 10 and 15 months of age in plasma but
not the brain. 19,20-diHDoPE and 17,18-diHETE are
stable metabolites of DHA and EPA, respectively, that
are mediated by cytochrome P450 (CYP) and soluble ep-
oxide hydrolase (EH). In mouse brain, CYP2C29,
CYP2C37, CYP2C38, and CYP2C40 were identified as
arachidonic acid epoxygenases [28] and appear to be re-
sponsible for EPA and DHA epoxidation. Furthermore,
soluble EH was reported to be expressed in various re-
gions of mouse brain, including the cerebral cortex and
hippocampus [29]. Levels of the intermediate metabo-
lites, 19,20-epoxy-docosapentaenoic acid (19,20-EpDPE)
and 17,18-epoxy-eicosatetraenoic acid (17,18-EpETE),
which are generated by P450 epoxygenase in neuronal
and glial cells, were below the quantification limit in
brain (data not shown) and thus appeared to be quickly
metabolized into their stable metabolites, 19,20-
diHDoPE and 17,18-diHETE, respectively. Although the
physiological functions of these metabolites in the cen-
tral nervous system are unknown, 19,20-EpDPE and
17,18-EpETE were shown to act as vasodilators in cere-
bral arteries [30]. Since increased blood pressure is a riskfactor for AD [31], these metabolites might counteract
the vasoconstrictive effects of Aβ. Furthermore, 17,18-
EpETE was reported to have anti-inflammatory proper-
ties mediated through PPARγ in lung tissues [32].
Therefore, 19,20-EpDPE and 17,18-EpETE in the brain
might play a protective role against the onset of AD, but
they are rapidly metabolized into their less active metab-
olites, 19,20-DiHDoPE and 17,18-diHETE. In this con-
text, the expression of microsomal EH was reported to
be significantly elevated in the hippocampus and associ-
ated cortex in AD patients [33]. However, the exact
mechanisms leading to the consistent increases in these
two compounds in brain and plasma remain unknown.
During the pre-symptomatic phase, docosahexaenoyl
lysoPC (22:6LPC) and eicosapentaenoy-lysoPC (20:5LPC)
in plasma were significantly higher in APP/tau mice than
in control mice (Table 3). LysoPC may represent a pre-
ferred physiological carrier of fatty acids to allow passage
across the blood–brain barrier [34], and thus brain DHA
and EPA might be at least partly supplemented by plasma
22:6LPC and 20:5LPC. The contribution of the lysoPC
species to supplementation of DHA and EPA in the brain
needs to be investigated.
A previous report showed that serum pPE levels were
higher in Alzheimer’s disease patients than in age-
matched controls [35] and increased Cer and decreased
SM levels in plasma were observed in patients with
early-stage AD [36]. However, these changes were not
observed in our APP/tau mice (Table 3).
Conclusions
We performed a lipidomic analysis using brain tissue
and plasma obtained from APP/tau mice at three AD
stages. Two lipid species, 38:2pPE (p18:1/20:1) and
22:6ChE, were consistently decreased and increased, re-
spectively, across the tested ages in APP/tau mice com-
pared to wild-type mice. As reported for human AD
brains, brain tissue from APP/tau mice showed in-
creased 12-HETE levels at the early symptomatic phase
and decreased levels of both pPEs and SMs with
medium chain fatty acids at the late symptomatic phase
compared with control mice. In addition to these previ-
ously reported changes, 19,20-diHDoPE and 17,18-
diHETE, the stable metabolites of 19,20-EpDPE and
17,18-EpETE that have a potential counteracting role for
AD, were increased in APP/tau brain tissue at the pre-
symptomatic phase, and concomitant increases in
plasma were observed. Furthermore, 15-HETE, which
has a potential protective role in AD, was decreased dur-
ing the early symptomatic phase in APP/tau mice. Our
results provide fundamental information on the further
precise analysis of lipids in AD pathogenesis. These
changes detected in APP/tau mice models of AD should
be examined in patients in the near future.
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Additional file 1: Figure S1. Expression levels of Aβ40 and tau proteins
in APP/tau mice. The levels of human Aβ40, and soluble (TBS-soluble plus
sarkosyl-soluble) and sarkosyl-insoluble APP/tau mice at 4, 10, and 15
months of age were determined by ELISA as described in Materials and
Methods. Values are mean ± SD of N = 3–5.
Additional file 2: Figure S2. RPLC-ESI-TOFMS analysis of brain lipids
from APP/tau and wild-type mice at 4 months of age. Total ion counts
chromatograph (TIC) and two-dimensional map with retention time (RT)
versus mass-charge (m/z) values of brain lipids measured by RPLC-ESI-
TOFMS in the positive ion mode from wild-type (A) and APP/tau mice
(B) at 4 months. The intensity of peaks is represented by color density spots.
Lipid metabolites were eluted in the following order: lysophospholipids
(Lyso PLs, LPLs) > phospholipids (PLs) = sphingomyelins (SMs) = ceramides
(Cers) > triacylglycerols (TAGs) = cholesterol esters (ChEs), as indicated in the
areas surrounded by the ellipses. Spots for ChEs were visible in APP/tau (B)
but not wild-type mice (A).
Additional file 3: Figure S3. Multivariate statistical analysis of brain lipids
between APP/tau and wild-type mice at 4 months of age. OPLS-DA score
plots and loading S-plots for brain tissues from APP/tau vs. wild-type mice
at 4 months, derived from the RPLC-ESI-TOFMS data set (A: 0.1-37.5min in
RT; B: 37.5-60min in RT). In score plots (wild-type is shown in open circle vs.
APP/tau in closed circle), the goodness-of-fit parameter R2 and the
predictive ability parameter Q2 were 1.000 and 0.840, respectively, for (A)
and 0.897 and 0.619, respectively, for (B). Loading S-plot showed covariance
w against correlation p (corr) of variables for discriminating components of
OPLS-DA model. Cut-off values for w[1] > |0.05| and p (corr) > |0.6| were
used to select metabolites that strongly contributed to the discrimination
between APP/tau and wild-type mice, which are surrounded by the red
dotted line.
Additional file 4: Table S1. Relative quantification of lipid species
meeting the OPLS-DA loading S-plot criteria in brain tissues.
Additional file 5: Table S2. Relative quantification of the detected
oxidized fatty acids in brain tissues).
Additional file 6: Figure S4. Pathway analysis of arachidonic acid
metabolites. HHT, hydroxy-heptadecatrienoic acid; HETE,
hydroxyeicosatetraenoic acid; EpETrE, epoxyeicosatrienoic acid; TX,
Thromboxane; COX, cyclooxygenase; LOX, lipoxygenase; CYP, cytochrome
P450; PGFS, prostamide/prostaglandin F synthase; PTGIS, Prostacyclin
synthase; PTGES, prostaglandin E synthase; PTGDS, prostaglandin D
synthase; TBXAS, thromboxane-A synthase.
Additional file 7: Table S3. Relative quantification of lipid species
meeting the OPLS-DA loading S-plot criteria in plasma.
Additional file 8: Table S4. Relative quantification of detected oxidized
fatty acids in plasma.
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